China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its SHR-4602 in combination with SHR-A2102, with or without adebrelimab (SHR-1316), in advanced solid tumors. This marks a significant step forward in the development of innovative therapies for patients with limited treatment options.
Drug Profiles and Mechanisms
SHR-4602 is an antibody drug conjugate (ADC) targeting HER2, designed to treat solid tumors with HER2 expression or mutation. SHR-A2102 is another ADC that targets Nectin-4, with a payload being a topoisomerase inhibitor (TOPi). Adebrelimab, a programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb), was approved in China in March 2023 for the treatment of first-line extensive stage small-cell lung cancer (ES-SCLC) in combination with chemotherapy.
Clinical Trial Outlook
The initiation of this clinical study represents a crucial milestone for Jiangsu Hengrui Pharmaceuticals. The trial will evaluate the safety and efficacy of the combination therapy, potentially offering new hope for patients with advanced solid tumors.-Fineline Info & Tech
Leave a Reply